Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

[Guest guest]

Yes! Thank you for posting this one, Sharon, n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Sharon-

This is scary! Seems kind of odd that a doctor would prescribe something that is known to cause suicidal behavior. I'm perplexed. Since I was just prescribed this by my own doctor, I'm not sure what to do now. One good thing is, I can't afford to have it filled at this time. Maybe I should make a phone call?

Thank you....Valene

-- FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Thanks n-

I will ask my doctor about this. I have already gotten to the point that I don't care if I live or die most of the time. But, never have I thought about taking my own life. And if there is any chance that this medicine may make me become suicidal, I don't want to be on it. I know some people who are taking effexor for their depression. But, from the symptoms they have gone through with that medicine, I know I don't want to be on it.

Yes, Monday, I am going to call my doctor and talk to her about this medication. And I'm also going to do a little Internet research as well.

God bless...

http://mscopgirl.blogspot.com

http://360.yahoo.com/vallee45

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Valene, just take goood care of YOU--you may care more about living as time passes. WE NEED YOU! Love,

n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Val, I was a slave to Paxil for several years. I finally got off of it November 2004. Thank God. I am now on Zoloft. I HATE Paxil with a passion. I totally understand how you feel. I used to wish I were dead, but never would I act on it. I just felt trapped in my life. Hugs to you, Trista

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Val...why did he prescribe it? If it is for depression, there are other things you can take that do not make you suicidal...like Sam-E and DLP (DL-Phenalalinine) (I think that's how it is spelled) and there's always good ol St 's Wort...I went through 5 years of PPD and I did have to take an anti-depressant to get over it, I took Lexapro, it does not have the same effect as the others as far as suicidal possibilities. Also know that the incidence of suicides from these drugs really are pretty small...but if you can get by with one of the more natural supplements you're going to be a LOT better off!!! I speak from experience.

Peace and Blessings

~*~ Akiba ~*~

Pragmatic Visionary

http://yodamamma.blogspot.com/

http://www.solay-twinflames.com

-- FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Akiba-

She said she was prescribing it for the depression and fatigue. Yes, I do think it's kind of strange that an antidepressant would also work for fatigue. I don't know. It's all very confusing to me. But, I have to agree with you, I also believe that if something can be treated naturally, that's always best. Like I said, I have not had the prescription filled yet. I'm going to see about getting things taken care of without all the drugs. I can't wait until they find some way to treat MS with something natural. I know what they make rebif out of and it just doesn't sit well with me.

God bless....Val

-- FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Val alot of drugs we are prescribed can be used for more than one thing.

Amitriptyline which I was on for 4 years was mainly for pain management but it did help with depression (a bit).

The burning sensation, it will not go away. It seems stronger and stronger, every day. The pain, it is intense. This illness, doesn't make any sense.http://ca.geocities.com/games_identity2001/filmcanisterlights.htmlhttp://www.mswebpals.org/amanda.htmhttp://ca.groups.yahoo.com/group/CanadaMS/ ReillyGirl Guides of CanadaEvergreen Division, White Oaks AreaMississauga, OntarioProgram Advisor

Akiba-

She said she was prescribing it for the depression and fatigue. Yes, I do think it's kind of strange that an antidepressant would also work for fatigue. I don't know. It's all very confusing to me. But, I have to agree with you, I also believe that if something can be treated naturally, that's always best. Like I said, I have not had the prescription filled yet. I'm going to see about getting things taken care of without all the drugs. I can't wait until they find some way to treat MS with something natural. I know what they make rebif out of and it just doesn't sit well with me.

God bless....Val

-- FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

,

I was prescribe Amitriptyline after the birth of my third child. I was given it for post-pardem depression. I only took it for a short time. In other words, I took it twice and threw the rest down the toilet. I had a new born baby. How was I supposed to take care of her, if I was too doped to function? It would knock me out. I don't even know how he knew I was suffering from ppd.

In hind sight, I think that may have not been the wisest decision I've ever made.

Blessed be...Val

-- RE: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Val alot of drugs we are prescribed can be used for more than one thing.

Amitriptyline which I was on for 4 years was mainly for pain management but it did help with depression (a bit).

The burning sensation, it will not go away. It seems stronger and stronger, every day. The pain, it is intense. This illness, doesn't make any sense.http://ca.geocities.com/games_identity2001/filmcanisterlights.htmlhttp://www.mswebpals.org/amanda.htmhttp://ca.groups.yahoo.com/group/CanadaMS/ ReillyGirl Guides of CanadaEvergreen Division, White Oaks AreaMississauga, OntarioProgram Advisor

[Guest guest]

, good post, and many anti-depressants DO reduce pain levels,

as depression makes one more suceptible to and aware of pain. Love to

you and thank you for your post, n

RE: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Val alot of drugs we are prescribed can be used for more than one thing.

Amitriptyline which I was on for 4 years was mainly for pain management but it did help with depression (a bit).

The burning sensation, it will not go away. It seems stronger and stronger, every day. The pain, it is intense. This illness, doesn't make any sense.http://ca.geocities.com/games_identity2001/filmcanisterlights.htmlhttp://www.mswebpals.org/amanda.htmhttp://ca.groups.yahoo.com/group/CanadaMS/ ReillyGirl Guides of CanadaEvergreen Division, White Oaks AreaMississauga, OntarioProgram Advisor

No virus found in this incoming message.Checked by AVG Anti-Virus.Version: 7.1.392 / Virus Database: 268.5.6/338 - Release Date: 5/12/2006

[Guest guest]

Hi Val, May I ask what the cost of the med is per month? Challis Valene wrote: Hello Challis- I was talking to my daughter yesterday. She was telling me that she's on Zoloft now. She was diagnosed with post-pardem depression and post traumatic shock. She says she does well on it. A couple of years back,

I was diagnosed with agoraphobia. My doctor put me on Zoloft. It had no effect on me. She then switched my to Paxil. I wasn't on it long enough to be able to really know how I was doing on it. I took myself off after it became too expensive for me to handle. I still haven't gotten my prescription filled. My fiance said he would pay for me to get it, but he won't be getting paid until Friday. I think I can live with that. In the meantime, I am going to continue to research and see if I can find a less expensive way to go with this. Thanks a bunch!! God bless...Val -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis

of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her citation, has a bad reputation. Love to you, Valene! n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young

adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior

was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at:

http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Challis-

For both meds together, the cost is $170.00 per month. I know it doesn't sound like much, but right now...$20.00 is too much.

Val

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm